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Cell cycle regulation in diabetic nephropathy. Renal hypertro- betic nephropathy [4–6]. Glomerular and tubular hyper-
phy is one of the earliest abnormalities of diabetic nephropathy. trophy is one of the earliest structural alterations of
Although selected cell populations, such as tubulointerstitial diabetic nephropathy [1, 7, 8].fibroblasts, may undergo sustained proliferation in the diabetic
Ultrasound investigations in humans document in-environment, most renal cells such as mesangial cells are ar-
creased overall renal size at the time of diagnosis of typerested in the G1-phase of the cell cycle after actively leaving G0-
phase and some self-limited early proliferation. High glucose, 1 diabetes [9]. Although one cannot be certain about the
transforming growth factor-beta (TGF-b), angiotensin II, and previous duration of the diabetic milieu in an individual
probably other factors induce inhibitors of cyclin-dependent patient before diagnosis, increased renal size is neverthe-kinases (CDK) including p21Cip1 and p27Kip1. These CDK-inhibi-
less one of the earliest organ alterations observed duringtors bind to and inactivate G1-phase cyclin/CDK complexes.
the course of diabetes. Furthermore, a correlation hasThe consequence is a lack in kinase activity, underphosphoryla-
tion of the retinoblastoma gene protein, and a failure to initiate been found between sonographically determined kidney
the G1-S-phase transit. The half-life of CDK-inhibitors may size and renal function over 8 years of follow-up such
also be increased by serine phosphorylation mediated through
that large kidneys in patients with type 1 diabetes andactivated MAP kinases. Treatment of diabetic rats with angio-
normal serum creatinine was a morphologic marker fortensin-converting enzyme inhibitors attenuates glomerular hy-
pertrophy and abolishes the glomerular expression of the subsequent deterioration of renal function [9]. Active
CDK-inhibitors p16INK4 and p27Kip1, thus indicating that the growth of nephrons is largely responsible for increased
cell cycle arrest can be therapeutically influenced. Cell cycle renal size, but hemodynamic mechanisms, such as hyper-
proteins may also be involved in these molecular events, lead-
filtration and hyperperfusion that leads to kidney hyper-ing to a limited degree of tubular apoptosis, which is a feature
emia, as well as osmotic changes also contribute to en-of diabetic nephropathy. Although not definitively proven, ac-
cumulating evidence suggests that early hypertrophy of renal largement of the kidneys [1, 10–14]
cells may act as pacemaker for subsequent irreversible struc- A controversial discussion continues over the years
tural changes, such as glomerulosclerosis and tubulointerstitial about whether changes in glomerular hemodynamics or
fibrosis. Therefore, a better understanding of altered processes
adaptive growth changes of the kidney are more impor-of cell cycle regulation is necessary to develop novel therapeu-
tant for the progression of diabetic nephropathy [14–16].tic strategies to prevent diabetic nephropathy. The recent ob-
servation that glomerular hypertrophy and proteinuria do not This disputed point, however, seems to have been re-
develop in diabetic p21Cip1 knockout mice indicates that this solved because hemodynamic changes and renal growth
approach is feasible. are intimately connected and may represent two faces
of the same coin. Hemodynamic changes, such as me-
chanical stretch or alterations in laminar flow, induce syn-
Diabetic nephropathy encompasses a complex of struc- thesis of specific growth factors, activate distinct signal
tural changes including renal hypertrophy, thickening of transduction pathways, and stimulate growth and extracel-
basement membranes, and progressive glomerular and lular matrix production in glomerular cells [17–19]. Many
tubulointerstitial accumulation of extracellular matrix of these changes are amplified in hyperglycemic situa-
components [1–3]. At least in the early phases of diabetic tions [1, 19]. Proteinuria, which is increased in glomerular
nephropathy, glomerular and tubulointerstitial infiltra- hyperdynamic states, influences activation, growth, and
tion of immunocompetent cells such as macrophages/ matrix synthesis of tubular cells fundamentally [20, 21].
monocytes occurs [4]. Furthermore, local proliferation Conversely, induction of renal growth, mediated by the
of both macrophages and myofibroblasts likely contrib- diabetic environment, may also eventually alter glomeru-
utes to the tubulointerstitial infiltrate observed in dia- lar hemodynamics, for example by an increase in capil-
lary filtration surface [1]. Finally, all vasoactive hor-
mones (e.g., angiotensin II [ANG II] or endothelin) exertKey words: diabetic nephropathy, hypertrophy, cell cycle regulation,
p27kip1, fibrosis, progression of renal disease. profound growth stimulatory actions on many renal cells,
particularly in the presence of high glucose [22–25].Ó 2000 by the International Society of Nephrology
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Table 1. Growth factors and peptides implicated in renal growthExpansion of the glomerular mesangium occurs within
during diabetes mellitus
a few years of the onset of insulin-dependent diabetes
Factor Referencemellitus and correlates closely with the deterioration in
Transforming growth factor-b 12, 72glomerular function [1, 7, 8]. Pathologic alterations of
Platelet-derived growth factor-b 10the tubulointerstitium such as tubulointerstitial fibrosis
Insulin-like growth factor-I 34
and tubular atrophy are also closely linked to the deterio- Insulin 10, 11
Hepatocyte growth factor 35ration of renal function in patients with diabetes of both
Tumor necrosis factor-a 11types 1 and 2 [2, 3]. Hypertrophy of the proximal tubule
Fibroblast growth factor 11
mainly accounts for the increase in kidney size in diabe- Vascular endothelial growth factor 38
Leptin 36tes because glomeruli alone account for less than 10%
Angiotensin II 19, 23of the kidney’s volume [1, 3]. Although it can be debated
Endothelin 1 39
whether initial adaptive renal growth, as observed in the
diabetic state, is causally linked to the irreversible later
changes such as glomerulosclerosis and tubulointerstitial
fibrosis, evidence is accumulating that suggests that this mic receptors [37]. However, we discovered that leptin
is indeed the case [1, 9]. Given that the growth response stimulates proliferation and synthesis of TGF-b in glo-
of every cell is dictated by the mechanisms of cell cycle merular endothelial cells in vitro and in vivo [36]. Fur-
regulation, an understanding of these molecular pro- thermore, leptin infusion in normal rats leads ultimately
cesses is essential for the development of novel therapeu- to proteinuria and segmental glomerular sclerosis [36].
tic strategies to prevent the development of diabetic ne- Preliminary evidence also suggests that leptin increases
phropathy. TGF-b receptor type 2 expression on mesangial cells indi-
cating a paracrine cross-talk between glomerular endothe-
lial and mesangial cells (abstract; Han et al, J Am SocRENAL GROWTH IN DIABETES
Nephrol 10:681A, 1999). Inasmuch as hyperleptinemia is
The particular growth response of a distinct renal cell
part of the metabolic syndrome in type 2 diabetes [36, 37],
(proliferation vs. hypertrophy) during the diabetic state
increased leptin concentrations could indeed modulate
depends on its intrinsic genetic program, which is specific growth of glomerular cells in diabetic nephropathy.
for the cell type, and the presence of growth factors in In addition to increased protein synthesis, a cell cycle–
the local environment [1, 10, 11]. Although all cells have independent decrease in proteinase activity leading to
the same cell cycle machinery, a distinct growth factor an attenuated turnover of structural and extracellular
may cause different growth responses in the kidney de- matrix proteins likely contributes to diabetic hypertro-
pending on the specific cell type. For example, trans- phy of the kidney [41–45]. Inhibition of such proteases
forming growth factor-b (TGF-b), a key factor in the may be caused by multiple factors including high glucose,
development of diabetic nephropathy, induces hypertro- advanced glycated end products (AGEs), ANG II, and
phy of mesangial, tubular cells, but also stimulates prolif- TGF-b [41, 44–46].
eration of tubulointerstitial fibroblasts [12, 26–29]. In
addition, ANG II exerts proliferative effects on some
CELL CYCLE REGULATIONrenal cells (mesangium cells, fibroblasts, distal tubular
cells) but also mediates hypertrophy of proximal tubules The growth of each cell is determined by different
[22, 25, 30–32]. These discriminatory effects are probably phases called the cell cycle (Fig. 1). The period between
caused by variations in growth factor receptor expression two mitoses, which defines the somatic cell cycle, is called
and coupling of these receptors to certain signal trans- the interphase. Renal cells, under normal conditions,
duction pathways [1]. Some of the multiple hormones, have a very low turnover rate of less than 1% [1, 47, 48].
cytokines, and growth factors [33–39], which have been These dormant cells can be considered to rest in a G0-
implicated in renal growth associated with diabetic ne- phase and have left the active processes of the cell cycle
phropathy, are shown in Table 1. Continuous production (Fig. 1). After stimulation with a growth factor or cyto-
and release of many of these growth factors during the kine, dormant cells actively enter the G1-phase in which
diabetic state cause not only renal growth as an integral cells increase their size and stimulate protein and mRNA
early part of diabetic nephropathy but may be also ulti- synthesis to prepare for DNA replication. Immediate
mately explain why patients with diabetes have a higher early genes, encoding various transcription factors, are
incidence of renal cancer [40]. also activated in the early G1-phase [48]. If conditions
One of the more recently characterized factors is lep- to pass the restriction point are satisfied, cells enter the
tin, traditionally not considered to be a growth factor S-phase after a short lag. During S-phase, the double
[36, 37]. Leptin is produced by adipocytes and reduces helix unfolds, DNA strands are separated, stabilized, and
DNA is replicated by polymerases. At the end of the S-food intake through interacting with specific hypothala-
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completely characterized, the cyclin/CDKs heterodimers
are activated and they exert kinase activity [48, 52]. For
example, a critical substrate for cyclin D/CDK4,6 com-
plexes that control G1-S-phase transit, is the protein
product of the retinoblastoma gene (pRB). On phos-
phorylation by active cyclin D/CDK4,6 kinases, hyper-
phosphorylated pRB releases the transcription factor
E2F that binds to the promoter regions of multiple target
genes which are essential for further cell cycle progres-
sion [48].
Kinase activity of cyclin/CDK complexes is also nega-
tively regulated by small proteins called CDK-inhibitors
(CKI). Two families of CKIs can be grouped according
to structural homology [48, 51]. Although common sense
may suggest that an overall increase in CKIs directly
inactivates cyclin/CDK complexes by simple binding to
those complexes and thus interfering with their kinase
activity, the situation is likely much more complex. For
example, the CKI p21Cip1 can inhibit cyclin/CDK com-Fig. 1. The different phases of the cell cycle. Quiescent cells are with-
plexes, but it may alternatively function as assembly fac-drawn form the cell cycle in G0-phase. After stimulation by growth
factors, cells reenter the cycle at G1 and prepare for DNA synthesis. tor cyclin D/CDK4 heterodimers [53]. CKIs can be also
After passing the restriction point in late G1, cells are committed to redistributed between different cyclin/CDK complexesenter the S-phase where DNA replication occurs. in G2, cells further
[48]. A decrease in synthesis of a specific cyclin may leadprepare for mitosis (M-phase) where cells divide. Cell cycle progression
is principally controlled by the kinase activity of cyclin/CDK-complexes. to release of CKIs, which then could bind and inhibit
other cyclin/CDKs complexes [51]. Finally, recent evi-
dence suggests that peptide fragments of CKIs, released
after ubiquitin-mediated proteolysis, could actually act
phase, the total content of DNA doubles to the fully as downstream activators of cyclin/CDK complexes facil-
replicated value of 4n. Cells prepare for mitosis in the itating cell cycle progression [48].
G2-phase then enter mitosis (M-phase), which itself is
composed of several distinct steps. After cell division, Cell cycle events in diabetic nephropathy
cells may start another cell cycle with reentering the G1- As depicted in Fig. 2 for mesangial cells, high glucose
phase or may, alternatively, withdraw from the active in vitro as well as the diabetic milieu in vivo result in a
cell cycle into the G0-phase (Fig. 1). biphasic growth response [12, 27]. Initially, the degree
Progression through the cell cycle and transition be- of proliferation is limited, followed by cell cycle arrest
tween different phases is controlled by a series of protein and hypertrophy [12, 27]. Mesangial cells exposed to high
kinases [48–54]. These active protein kinases are holoen- glucose actively enter the cell cycle as demonstrated by
zymes composed of two subunits: cyclins and their part- expression of immediate early genes such as c-fos, c-jun,
ner cyclin-dependent kinases (CDK). Some cyclin/CDK and Egr-1 [55–57]. After one or two complete rounds of
complexes act only in specific cell phases whereas others cell-cycle progression with completion of mitosis, cells
are more widely distributed [52]. Regulation of these are arrested in the G1-phase and undergo hypertrophy
cyclin/CDK complexes in the kidney has been reviewed [12]. This change in phenotype is mediated by TGF-b
[48, 51, 53, 54]. In brief, cyclins have short half-lives (less because a neutralizing anti-TGF-b antibody prevented
than 60 min) and their protein levels fluctuate through- the late inhibitory effects of high glucose on hypertrophy
out the cell cycle with increasing synthesis and subse- of mesangial cells [12].
quent degradation by the ubiquitin-proteasome complex
Cell cycle regulation of mesangial cells in diabetes[51, 53]. Transcription and synthesis of various cyclins
may be negatively or positively controlled through spe- To gain a better insight into the molecular mechanisms
cific growth factors. In contrast, CDKs are constitutively surrounding this high glucose–mediated G1-phase arrest,
expressed, and their activity depends on binding to we and others investigated the regulation of CKIs. Incu-
cyclins and phosphorylation. Cyclins accumulate during bation of mouse mesangial cells, in the absence of other
specific phases of the cell cycles and bind, after reaching factors for 48–96 h, in culture medium with high glucose
a critical concentration, to their putative CDK partners. stimulated p27Kip1 protein expression but did not influ-
Subsequent to complex phosphorylation and dephos- ence mRNA abundance [58]. These effects were inde-
pendent of the osmolarity of the medium. High glucose–phorylation steps whose upstream effectors remain in-
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Fig. 2. Development of mesangial cell
growth in diabetic nephropathy. Experiments
in diabetic animals as well as cell culture stud-
ies of mesangial cells exposed to ambient high
glucose indicate a biphasic growth response.
There is an early, self-limited degree of prolif-
eration indicating reentry and progression
through the cell cycle. This proliferation is
followed by sustained hypertrophy of mesan-
gial cells being associated with an increase
in synthesis and deposition of extracellular
matrix proteins. Eventually, end-stage dia-
betic nephropathy with glomerular sclerosis,
tubular atrophy, tubulointerstitial fibrosis, and
irreversible loss of renal function will evolve.
stimulated expression of p27Kip1 involved the activation gate a functional role of p27Kip1 in high glucose–mediated
mesangial hypertrophy, we compared the growth behav-of PKC and partly depended on induction of TGF-b
[58]. p27Kip1 protein, induced by high glucose, mainly ior of mesangial cells cultured from p27Kip11/1 and 2/2
mice. In contrast to p27Kip1 wild-type cells, high glucosebound to CDK2 but not to CDK4 [58]. p27Kip1 antisense,
but not missense, oligonucleotides inhibited high glu- did not increase hypertrophy in p27Kip1 2/2 mesangial
cells. Reconstitution of p27Kip1 expression in 2/2 cellscose–stimulated total protein synthesis and converted
the hypertrophy into a proliferative phenotype sug- using an inducible expression system led to G1-phase
arrest. However, mesangial hypertrophy was only ob-gesting G1-phase exit [58] We extended these studies to
diabetic db/db mice, a model of type 2 diabetes [59]. served when p27Kip1 was induced in high glucose, sug-
gesting that p27Kip1-mediated G1-phase arrest is a neces-Glomerular p27Kip1 protein, but not mRNA expression,
was strongly enhanced in diabetic db/db mice compared sary prerequisite, but this alone was not sufficient for
the development of hypertrophy (abstract; Wolf et al,with nondiabetic db/1 littermates [59]. Immunohisto-
chemical studies revealed that this stimulated expression J Am Soc Nephrol 10:692A, 1999).
In accordance with this observation, Kuna and co-was due to an increase in mesangial and endothelial
staining for p27Kip1 [59]. Primary cultures of mesangial workers studied the expression of p21Cip1 in experimental
diabetic nephropathy [65]. They found a progressive in-cells from db/1 and db/db revealed a low p27Kip1 expres-
sion when cultured in normal glucose–containing me- crease in mesangial cells that stained positive for p21Cip1
at days 3 and 9 after induction of diabetes with streptozo-dium [59]. However, increasing the glucose concentra-
tion of the medium induced p27Kip1 expression in both cell tocin compared with normoglycemic control mice [65].
This increase in p21Cip1 was associated with glomerularlines and arrested the cells in the G1-phase. Glomerular
p27Kip1 protein also increased in the murine streptozo- hypertrophy. Furthermore, cellular hypertrophy, in-
duced in cultured mesangial cells exposed to high ambi-tocin type 1 diabetes [59]. These data clearly indicate that
the stimulated mesangial expression of p27Kip1 in db/db ent glucose concentration, was also associated with an
increase in p21Cip1 protein expression, whereas the levelsmice compared with normoglycemic littermates is caused
by high glucose and not by additionally genetic effects of p57Kip2, another member of the CIP/KIP family of
CKIs, did not change [65]. The most direct evidence for[59]. Moreover, ANG II also induces p27Kip1 expression
in renal cells [60, 61]. This mechanism may contribute p21Cip1 as a pivotal regulator of glomerular hypertrophy
comes from studies of Shankland’s group who inducedto p27Kip1 expression in diabetic nephropathy in vivo be-
cause the intrarenal renin-angiotensin system is activated experimental type 1 diabetes in p21Cip1 knockout mice
[66]. The glomerular tuft area increased significantly induring diabetes [19, 23]. We have obtained preliminary
evidence that mitogen-activated protein (MAP)-kinases diabetic p21Cip1 1/1 mice at day 60 compared with con-
trols indicating glomerular hypertrophy [66]. Despite in-directly phosphorylates p27Kip1 and increases its stability
(abstract; Wolf et al, J Am Soc Nephrol 10:465 A, 1999). creased glomerular TGF-b mRNA expression, diabetic
p21Cip1 2/2 mice did not develop glomerular hypertro-Because MAP kinases are activated in cultured mesan-
gial cells exposed to high glucose and in glomeruli from phy [66]. Moreover, diabetic p21Cip1 1/1 mice, but not
p21Cip1 2/2 mice, become proteinuric compared withdiabetic rats [62–64], it is possible that phosphorylation
of p27Kip1 partly contributes to the induced expression nondiabetic controls [66]. Interestingly, tubular but not
glomerular proliferation was increased in diabetic p21Cip1observed in the diabetic environment. To further investi-
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2/2 mice [66]. These data provide overwhelming evi- ever, it has been alternatively described in nonrenal sys-
tems that TGF-b decreases expression of CDK4 anddence that p21Cip1 is necessary for the development of
diabetic hypertrophy and that a loss of this CKI prevents also induces the CDK4-specific inhibitor p15INK4b [76, 77].
These changes disrupt binding of CKIs such as p27Kip1the functional consequences of glomerular hypertrophy
such as proteinuria [66]. to cyclin D/CDK4 complexes leading to a redistribution
and binding to cyclin E/CDK2 with kinase inhibition ofIt is well known that angiotensin-converting enzyme
(ACE) inhibitor treatment prevents glomerular hyper- these complexes [76, 77].
High glucose and/or TGF-b cause sustained prolifera-trophy in diabetes mellitus [15, 67, 68]. We recently
tested the effects of enalapril on glomerular expression tion of some renal cell types such as tubulointerstitial
fibroblasts [26, 78, 79]. Moreover, other cells such as glo-of CKIs in BBdp rats, an autoimmune model of type 1
diabetes [69]. Glomerular expression of p16INK4, p21Cip1, merular endothelial cells extensively progress through the
cell cycle despite autocrine synthesis and secretion ofand p27Kip1 were all stimulated in BBdp rats compared
with findings in nondiabetic BBdr animals [69]. Enalapril TGF-b [36]. Indeed, an increase in glomerular capillaries
was found diabetic rats [80]. Why TGF-b fails to inducetreatment for 3 weeks reduced the glomerular expression
of p16INK4 and p27Kip1 but not of p21Cip1 [69]. The ACE G1-phase arrest in these cells remains currently unclear,
but this may be due to changes in TGF-b receptor surfaceinhibitor treatment also prevented renal hypertrophy,
but had, in the dosage used, no effect on systolic blood expression, signal transduction pathways, or specific
changes in cell cycle regulation in these cells. Thus, al-pressure or glucose concentration [69]. These data dem-
onstrate that ACE inhibitor treatment attenuates glo- though most renal cells undergo hypertrophy in diabetes
mellitus, limited cell populations within the kidney maymerular hypertrophy in diabetes by interfering with the
expression of selected CKI [69]. Although it remains proliferate [1, 78, 79].
unclear whether these effects are due to ANG II itself
Apoptosis as a cell cycle–dependent mechanismor are caused by normalization of glomerular hemody-
namics, these findings provide strong evidence that mod- Although apoptosis of glomerular cells seems not to
be a relevant feature of diabetic nephropathy [65, 66],ulation of renal cell cycle events is feasible in diabetes
mellitus. apoptosiss of tubular cells increases [81]. This increase
in apoptosis is associated with a decrease in bcl-2 expres-
Cell cycle regulation of tubulointerstitial cells sion and an increase in bax gene expression, which pre-
in diabetes disposes to cell death by binding to and inhibiting bcl-2
[81]. An increase in apoptosis, forced onto tubular cellsThe role of tubular hypertrophy in the progression
of diabetic nephropathy has been indicated [2, 3, 70]. by the diabetic environment, may partly explain tubular
atrophy, a feature of advanced diabetic nephropathy [2,Ziyadeh and coworkers were the first to describe that
high glucose induces hypertrophy of cultured proximal 3, 82]. Recent evidence suggest that cell cycle regulatory
proteins are involved in apoptotic mechanisms [48, 82–tubular cells, a response mediated by autocrine TGF-b
[71, 72]. In the early 1990s, Fine and colleagues provided 85]. Studies have shown that cells typically exit the cell
cycle in late G1-phase during apoptosis. It appears thatevidence that TGF-b transforms a mitogenic stimulus
into hypertrophy [73]. At that time, TGF-b was not even CKIs may be important in preventing apoptosis because
apoptosis is markedly increased in nephritic p27Kip1 2/2known under its current name [73]. Franch and associates
investigated more recently the cell cycle mechanism un- mice compared with control p27Kip11/1 animals [83].
Moreover, apoptosis induced by growth factor depriva-derlying this TGF-b-mediated hypertrophy in tubular cells
and found that these cells actively enter the G1-phase tion or cycloheximide is markedly increased in p27Kip1
2/2 cells and is prevented by reconstituting p27Kip1 levelsfrom G0, but do not progress further [74]. The molecular
mechanisms underlying this G1-phase arrest is an inhibi- [84]. Carboxyl-termini of p21Cip1 and p27Kip1 are truncated
by caspases in nonrenal cells [85]. Thus, cell cycle regula-tion of cyclin E/CDK2 kinase activity without influencing
cyclin D/CDK4 complexes [74, 75]. Because overall syn- tory proteins may also be directly involved in apoptosis.
A unifying cell cycle regulatory model for mesangialthesis of cyclin E or CDK 2 does not change after TGF-b
treatment, it is likely that induction of CKI such as p57Kip2 and tubular cell hypertrophy in diabetic nephropathy
is proposed in Fig. 3. Cells subjected to the diabeticoccurs and subsequent binding to the heterodimers is
responsible for the attenuated cyclin E/CDK2 kinase environment actively enter the G1-phase and may com-
plete one or two mitoses. These cells then become growthactivity [75]. This inhibition of cyclin E/CDK2 kinase
maintains pRB in its underphosphorylated form pre- arrested in late G1-phase and undergo hypertrophy. The
induction of CKIs such as p21Cip1 and p27Kip1 is pivotalventing cell cycle progression [74, 75]. Similar mecha-
nisms with an activated cyclin D, but with inhibition of for this arrest. High glucose and other factors such as
ANG II and AGEs induce TGF-b. TGF-b in turn stimu-cyclin E kinase complexes, have been described in tubu-
lar cells in the streptozotocin model at day 10 [52]. How- lates the expression of p21Cip1 and p27Kip1. Other CKIs
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Fig. 3. Central role of CKI inhibitors
p21Cip1 and p27Kip1 in high glucose-induced
G1-phase arrest. High glucose as well as other
factors (ANG II, AGEs, mechanical stretch)
all induce TGF-b. TGF-b in turn stimulates
the expression of the CDK-inhibitors p21Cip1
and p27Kip1. The high glucose-mediated induc-
tion of p27Kip1 is to some extent independent
of TGF-b. High glucose additionally activates
MAP kinases which phosphorylate and may
stabilize p27Kip1. Both CDK-inhibitors, likely
in concert, mediate G1-phase arrest by binding
to and inhibiting G1-phase cyclin/CDK com-
plexes. Moreover, it has been shown that
TGF-b leads to a downregulation of cyclin D
as well as induction of p16INK4 with a potential
liberation of p27Kip1 that could now bind to
cyclin E and further reinforce the G1-phase
arrest (! 5 stimulation, - - -c 5 inhibition).
(p16INK4, p57Kip2) may play additional roles [69, 75]. The of personal experience in treating patients with diabetes
high glucose-mediated induction of p27Kip1 is to some mellitus, the excessive incidence of renal disease in dia-
extent independent of TGF-b. High glucose activates betes mellitus [86]. In the last sentence of the article
MAP kinases, which, in turn, phosphorylate and may summarizing his lifework, Joslin imagined: “that the next
further stabilize p27Kip1. Both CDK-inhibitors, likely in 50 years hold more of promise than the last” [86]. This
concert, mediate G1-phase arrest by binding to and inhib- hope has unfortunately not been fulfillled. Although the
iting G1-phase cyclin/CDK complexes. Moreover, it has mortality of patients with type 1 diabetes declined over
been shown that TGF-b leads to a down-regulation of the past years, the spectrum of diabetes has been ex-
cyclin D as well as induction of p16INK4 with a potential panded by type 2 diabetes [87], a disease largely unknown
liberation of p27Kip1 that could now bind to cyclin E and to Joslin. The exponentially increasing number of patients
further reinforce the G1-phase arrest. entering chronic dialysis programs with renal failure re-
sulting from type 2 diabetes in the face of dwindling
economic resources and the exceptionally high mortalityCONCLUSION
rates of these patients receiving dialysis necessitates a
Renal growth is one of the earliest features of diabetic better insight into early pathophysiologic processes of
nephropathy [1]. Although some distinct cell populations diabetic nephropathy to prevent the progression of dis-
such as tubulointerstitial fibroblast exhibit proliferation, ease [87]. Hypertrophy of renal cells is an early abnor-
most renal cells including mesangial and tubular cells mality of diabetic nephropathy and is caused by changes
are growth arrested in the G1-phase of the cell cycle, after in cell cycle regulation forced onto renal cells through
an initial limited degree of proliferation, and undergo
the diabetic milieu. Although not definitively proven,
cellular hypertrophy. Accumulating data over the last
accumulating evidence suggests that this early hypertro-
few years have provided convincing evidence that this
phy may act as pacemaker for the subsequent irreversiblehypertrophy requires the induction of specific cell cycle
structural changes such as glomerulosclerosis and tubu-proteins such as CKIs. The CKIs p21Cip1 and p27Kip1 are
lointerstitial fibrosis. It is imaginable that prevention ofinduced by high glucose (and possibly other factors of the
hypertrophy by modifying cell cycle events in diabetesdiabetic milieu), and bind to cyclin E/CDK2,4 complexes
mellitus may prevent progression of diabetic nephropa-and inhibit their kinase activity. The result is the under-
thy. In this regard, “size does really matter” [88].phosphorylation of pRB with retention of transcription
factor E2F and a failure to exit G1-phase. Diabetic renal
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